Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib
스크롤 이동 상태바
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib